For one, the AUC of all predictors were lower in patients with PSA 4–10 ng/ml than in the overall patients (Table 2); also, because the difference of PZ-ratio between PCa and non-cancer patients in this subgroup was relatively smaller than in the overall population; or, it may result from insufficient sample size; nevertheless, decision curve analysis indicated that the model with PZ-ratio and MRI-findings was able to significantly reduce the number of unnecessary biopsies at the cost of similar or less significant PCa missed in all patients and patients with PSA 4–10 ng/ml. Here, KLK3 is linked to cancer.